Undifferentiated Pleomorphic Sarcoma
Promising Objective Response Rate (ORR) Observed in Phase II Trial of Envafolimab for Sarcoma
SG Tylor
Source: TRACON Pharmaceuticals Positive findings from the ongoing Phase II ENVASARC trial (NCT04480502) demonstrate that envafolimab (KN035), either as a ...
